Latest News and Press Releases
Want to stay updated on the latest news?
-
Company records $35.7 million in total net product sales Company now expects full-year revenues for JUXTAPID to be between $90 million and $100 millionCompany continues to...
-
CAMBRIDGE, Mass., May 12, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (“Aegerion” or the “Company”) (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and...
-
CAMBRIDGE, Mass., May 11, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
-
CAMBRIDGE, Mass., May 06, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
-
CAMBRIDGE, Mass., April 11, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company dedicated to the development and commercialization of innovative...
-
CAMBRIDGE, MA, March 31, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics to...
-
CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), una compañía biofarmacéutica dedicada al desarrollo y a la comercialización de terapias...
-
CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- A Aegerion Pharmaceuticals, Inc.(NASDAQ:AEGR), uma empresa biofarmacêutica com foco no desenvolvimento e na comercialização de novos produtos...
-
CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...
-
CAMBRIDGE, Mass., March 31, 2016 (GLOBE NEWSWIRE) -- Aegerion Pharmaceuticals, Inc. (NASDAQ:AEGR), a biopharmaceutical company focused on the development and commercialization of novel therapeutics...